Rituximab and antithymocyte globulin reduce the incidence of aGVHD more efficiently than antithymocyte globulin alone
| Grades . | Rituximab + ATG . | ATG . | Rituximab . | No ATG, no rituximab . |
|---|---|---|---|---|
| aGVHD II-IV | 0/10 | 5/17 (29.4%)* | 3/3 | 4/4 |
| aGVHD I-IV | 0/10 | 10/17 (58.8%)* | 3/3 | 4/4 |
| Grades . | Rituximab + ATG . | ATG . | Rituximab . | No ATG, no rituximab . |
|---|---|---|---|---|
| aGVHD II-IV | 0/10 | 5/17 (29.4%)* | 3/3 | 4/4 |
| aGVHD I-IV | 0/10 | 10/17 (58.8%)* | 3/3 | 4/4 |
ATG indicates antithymocyte globulin.
P < .001 by χ2 test.